Currently, a majority of cancer treatment strategies are based on the removal of tumor mass
mainly by surgery. Chemical and physical treatments such as chemo-and radiotherapies …

Pancreatic cancer has been classified as a cancer of unmet need. After diagnosis the patient
prognosis is dismal with few surviving over 5 years. Treatment regimes are highly patient …

Liposomes are applied to various anticancer treatments as representative drug delivery
carriers. However, liposomes do not have their own targeting properties; therefore, there are …

Gemcitabine (Gem) is a standard first-line treatment for pancreatic cancer (PC). However, its
chemotherapeutic efficacy is hampered by various limitations such as short half-life …

Multifunctional nanocarriers are presently used to solve crucial unmet challenges in cancer
treatment. In this project, we reported an intelligent amine mesoporous silica (MSN-NH2) …

Gemcitabine (GEM) is widely used in clinical practice in the treatment of cancer and several
other solid tumors. Nevertheless, the antitumor effect of GEM is partially prevented by some …

吉西他滨作为恶性肿瘤临床治疗一线药物, 目前存在不能口服, 易被脱氨酶代谢, 生物利用度低,
易产生耐药性等缺陷. 近年来, 为了改善吉西他滨的上述缺陷, 研究者们利用前药设计策略 …

This chapter covers scientific contributions in quinquevalent organo-phosphorus chemistry
published in the literature in 2021. The review is not comprehensive but shows the most …

As the first-line therapy of malignant tumor, gemcitabine is compromised by inability to be
taken orally, rapid metabolism by deaminase, low bioavailability and easy development of …

Pancreatic cancer or pancreatic ductal adenocarcinoma (PDAC), is the deadliest type of
cancerous malignancy with a survival rate of only 3.7% after 5 years. The first line current …